Loading
MeiraGTx Holdings plc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 Aug 2024.
MeiraGTx Holdings plc: what insiders have been doing
MeiraGTx Holdings plc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 9 insiders have disclosed 34 filings since 18 October 2025.
Only sales appear on the open market, 9 sales in all totalling €3.3M, filed by 3 insiders. Biggest ticket of the year: €742k, sold by Forbes Alexandria and made public on 18 August 2026 (0.081% of market cap).
For context, the typical company on the same exchange (median of 5,808 companies) published 19 filings over the same period, against 34 filings here. Our records for MeiraGTx Holdings plc go back to 2021, with 4 purchases and 22 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 81.4 m USD and net income of -114.2 m USD.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
99
Thresholds
n/a
Buy Volume
€27M
4 ops. · all time
Sell Volume
€6M
22 ops. · all time
Who traded when
BuySaleRichard Giroux6 sales
Alexandria Forbes5 sales
Naylor Stuart4 sales
Since the insiders bought
- +85.7%Entry US$4.40 · Close at T+365 US$8.17
- -6.9%Entry US$8.25 · Close at T+365 US$7.68
- -17.1%Entry US$8.23 · Close at T+365 US$6.82
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,954 of 24,148 companies
58.0
score / 100
Value19
Quality97
FCF yld-5.3%
Earn yld-12%
EV/EBITDA·
ROE72%
Gross mgn94%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.94
Analyst consensus
8 analysts1.50/5
US$16.00Target US$27.75(+179%)US$50.00
Income statement
RevenueUS$81.4M
Gross profitUS$76.5M94% margin
EBITDA-US$89.4M-110% margin
Net income-US$114.2M19.9% margin
Valuation
PER (trailing)11.4x
PER (forward)-6.5x
P/Book4.3x
Beta1.35
Balance sheet & cash
Market capUS$954.7M
Total debtUS$88.7M
Free Cash Flow-US$50.6M
Debt / Equity52%
Profitability & ownership
ROE72.2%
ROA38.7%
% insiders16.3%
% institutions70.5%
Last declaration on 6 October 2026
Declarations99 total
27,659 shares@ US$10.6410.028% mcap14.7% of flowOrdinary SharesSEC144:0001959173-26-007300
27,659 shares@ US$10.640.028% mcap17.3% of flowOrdinary SharesSEC:0001742771-26-000014:0
62,000 shares@ US$13.860.081% mcap100.0% of flowOrdinary SharesSEC144:0001678604-26-000019
62,000 shares@ US$13.860.081% mcap28.6% of flowOrdinary SharesSEC:0001678604-26-000020:0
56,000 shares@ US$12.510.067% mcap100.0% of flowOrdinary SharesSEC144:0001742734-26-000017
56,000 shares@ US$12.510.067% mcap35.0% of flowOrdinary SharesSEC:0001742734-26-000018:0
27,659 shares@ US$13.330.035% mcap25.7% of flowOrdinary SharesSEC144:0001959173-26-005127
2,547 shares@ US$13.860.0033% mcap2.5% of flowOrdinary SharesSEC:0001742771-26-000012:0
25,112 shares@ US$14.900.036% mcap26.1% of flowOrdinary SharesSEC:0001742771-26-000012:1
7,000 shares0Ordinary SharesSEC:0001742734-26-000012:0
7,814 shares@ US$7.7330.8% of flowOrdinary SharesSEC:0001745347-26-000008:0
555,555 shares@ US$9.000.36% mcap9.0% of flowOrdinary SharesSEC:0001193125-26-174407:0
56,000 shares@ US$10.220.041% mcap27.8% of flowOrdinary SharesSEC:0001742734-26-000010:0
27,661 shares@ US$9.3617.7% of flowOrdinary SharesSEC:0001742771-26-000008:0
62,000 shares@ US$7.4115.3% of flowOrdinary SharesSEC:0001678604-26-000010:0
62,500 sharesOrdinary SharesSEC:0001678604-26-000006:0
11,250 sharesOrdinary SharesSEC:0001815161-26-000006:0
7,500 sharesOrdinary SharesSEC:0001745347-26-000006:0
25,000 sharesOrdinary SharesSEC:0001742771-26-000006:0
60,000 sharesOrdinary SharesSEC:0001742734-26-000006:0
50,000 sharesOrdinary SharesSEC:0001815161-26-000004:0
35,000 sharesOrdinary SharesSEC:0001745347-26-000004:0
75,000 sharesOrdinary SharesSEC:0001742771-26-000004:0
310,000 sharesOrdinary SharesSEC:0001742734-26-000004:0
310,000 sharesOrdinary SharesSEC:0001678604-26-000004:0
25 of 99 declarations
About MeiraGTx Holdings plc
MeiraGTx Holdings plc (NASDAQ: MGTX) is a US-listed genetic medicines company focused on gene therapy and gene regulation platforms. Although the holding company is organized under non-US corporate law, the business has major operating and strategic centers in London and New York and is built around a vertically integrated model that combines discovery, manufacturing, quality control, and clinical development. That integrated structure is a core part of the equity story because it gives MeiraGTx more control over vector production, process development, and potential commercial supply than many early-stage peers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1735438/000110465926060739/mgtx-20260331x10q.htm?utm_source=openai))
The company was founded to address high-unmet-need diseases with gene-based medicines. Over time, it has evolved from a predominantly ocular gene therapy story into a broader genetic medicines platform. According to its 2025 annual report, MeiraGTx has invested heavily in internal manufacturing capabilities, including facilities for viral vector production, plasmid DNA manufacturing, and advanced quality-control testing. Management emphasizes this in-house infrastructure as a strategic advantage for both clinical execution and future commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001735438/000110465926036494/mgtx-20251231x10k.htm?utm_source=openai))
Read moreShow less
MeiraGTx’s main development programs currently center on four late-stage clinical areas spanning ophthalmology, salivary gland disorders, and neurology. Key assets include bota-vec for X-linked retinitis pigmentosa, AAV-hAQP1 for radiation-induced xerostomia, and AAV-GAD for Parkinson’s disease. The company also continues to develop its riboswitch gene regulation platform, which is designed to enable dose-responsive expression of biologics using oral small molecules and could expand the platform into broader therapeutic categories over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001735438/000110465926036494/mgtx-20251231x10k.htm?utm_source=openai))
In competitive terms, MeiraGTx sits in a highly capital-intensive segment where execution risk remains elevated. Its differentiation comes from the combination of proprietary vector engineering, internal manufacturing scale, and a pipeline that includes both disease-targeted clinical programs and a more ambitious gene regulation platform. However, like most clinical-stage biotech companies, it remains pre-profit and has not yet generated meaningful product revenue, so valuation is driven primarily by clinical data, regulatory milestones, partnership economics, and financing capacity. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001735438/000110465926036494/mgtx-20251231x10k.htm?utm_source=openai))
Recent developments are especially relevant for investors. In April 2026, MeiraGTx announced an underwritten equity offering of roughly $100 million, which should strengthen near-term funding flexibility. Around the same time, it completed an asset purchase related to an ophthalmology program previously associated with Janssen, further reinforcing the retinal gene therapy franchise. The company’s May 2026 corporate update suggests ongoing progress across its pipeline as it works toward potential late-stage value inflection points and, if successful, future commercial launches in the United States market. ([investors.meiragtx.com](https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-announces-pricing-100-million-offering-ordinary-shares?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
